Skip to main content
SpringerLink
Log in

Minimising the Adverse Effects of Ketorolac

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Gastrointestinal bleeding and perforation, platelet inhibition with altered haemostasis, and renal impairment are among the list of adverse effects associated with the administration of ketorolac. The incidence of serious adverse events has declined since dosage guidelines were revised. Most of the published literature suggests that the overall risk of gastrointestinal or operative site bleeding related to ketorolac therapy is only slightly higher than with opioids. The risk for adverse events, however, increases with high doses, with prolonged therapy (>5 days) or in vulnerable patients (e.g. the elderly). Acute renal failure has been reported after ketorolac treatment but is usually reversible after discontinuation of the drug. As with other nonsteroidal anti-inflammatory drugs (NSAIDs), ketorolac may trigger allergic or hypersensitivity reactions.

Careful patient selection is essential if use of ketorolac is considered. Contraindications to ketorolac use include a history of, or current risk of, gastrointestinal bleeding, risk of renal failure, compromised haemostasis, hypersensitivity to aspirin (acetylsalicylic acid) or other NSAIDs, labour, delivery and nursing. Ketorolac should be prescribed at the lowest dosage necessary to control pain; the duration of therapy should also be limited to as few days as possible. Practitioners should be familiar with, and follow, label warnings and dosage guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Council of International Organizations of Medical Sciences. Final report of CIOMS Working Group II. International reporting of periodic drug-safety update summaries. Geneva: Council of International Organizations of Medical Sciences, World Health Organization, 1992

  2. Lewis S. Ketorolac in Europe [letter]. Lancet 1994; 343: 784

    Article  Google Scholar 

  3. Gillis JC, Brogden RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53: 139–88

    Article  PubMed  CAS  Google Scholar 

  4. Anonymous. New ketorolac dosage recommendations. Pharm J 1993; 251: 49

  5. Ketorolac: restrictions on parenteral dosage, WHO Drug Info 1993; 7 (2): 64

  6. Bruno JJ, Yang D, Taylor LA. Differing effects of ticlopidine and two prostaglandins synthetase inhibitors on maximum rate of ADP-induce aggregation [abstract]. Thromb Haemost 1981; 46: 412

    Google Scholar 

  7. Antiplatelet Trialists’Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Google Scholar 

  8. Greer IA. Effects of ketorolac tromethamine on hemostasis. Pharmacotherapy 1990; 10(6): 71S–6S

    PubMed  CAS  Google Scholar 

  9. Conrad KA, Fagan TC, Mackie MJ, et al. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther 1988; 43: 542–6

    Article  PubMed  CAS  Google Scholar 

  10. Concannon MJ, Meng L, Welsh CF, et al. Inhibition of perioperative platelet aggregation using toradol (ketorolac). Ann Plast Surg 1993; 30(3): 264–6

    Article  PubMed  CAS  Google Scholar 

  11. Thwaites BK, Nigus D, Bouska GW, et al. Intravenous ketorolac tromethamine worsened platelet function during knee arthroscopy under spinal anesthesia. Anesth Analg 1996; 82: 1176–81

    PubMed  CAS  Google Scholar 

  12. Thwaites BK, Nigus D, Bouska GW, et al. Intravenous ketorolac tromethamine does not worsen platelet function during knee arthroscopy under general anesthesia. Anesth Analg 1995; 81: 119–24

    PubMed  CAS  Google Scholar 

  13. Weale AE, Durant N, Warwick DJ, et al. Is there a clinical interaction between low molecular weight heparin and nonsteroidal analgesics after total hip replacement? Ann R Coll Surg Engl 1995; 77: 35–7

    PubMed  CAS  Google Scholar 

  14. Koh SCL, Pua HL, Tay DHB, et al. The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion. Thromb Res 1995; 79: 501–14

    Article  PubMed  CAS  Google Scholar 

  15. Varrasi G, Panella L, Piroli A. The effects of perioperative ketorolac infusion on postoperative pain and endocrine-metabolic response. Anesth Analg 1994; 78: 514–9

    Article  Google Scholar 

  16. Watcha MF, Ramirez-Ruiz M, White PF, et al. Perioperative effects of ketorolac and acetaminophen in children undergoing bilateral myringotomy. Can J Anaesth 1992; 39: 649–54

    Article  PubMed  CAS  Google Scholar 

  17. Watcha MF, Barry Jones M, Lagueruela RG, et al. Comparison of ketorolac and morphine as adjuvants during pediatric surgery. Anesthesiology 1992; 76: 368–72

    Article  PubMed  CAS  Google Scholar 

  18. Munro HM, Riegger LQ, Reynolds PI, et al. Comparison of the analgesic and emetic properties of ketorolac and morphine for paediatric outpatient strabismus surgery. Br J Anaesth 1994; 72: 624–8

    Article  PubMed  CAS  Google Scholar 

  19. Hall SC. Tonsillectomies, ketorolac, and the march of progress. Can J Anaesth 1996; 436: 544–8

    Article  PubMed  CAS  Google Scholar 

  20. Gunter JB, Varughese AM, Harrington JF, et al. Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Anesth Analg 1995; 81: 1136–41

    PubMed  CAS  Google Scholar 

  21. Judkins JH, Dray TG, Hubbell RN. Intraoperative ketorolac and posttonsillectomy bleeding. Arch Otolaryngol Head Neck Surg 1996; 112: 937–40

    Article  Google Scholar 

  22. Splinter WM, Rhine EJ, Roberts DW, et al. Preoperative ketorolac increases bleeding after tonsillectomy in children. An J Anaesth 1996; 43; 6: 560–3

    CAS  Google Scholar 

  23. Bailey R, Sinha C, Burgess PA. Ketorolac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, doubleblind study. Laryngoscope 1997; 107: 166–9

    Article  PubMed  CAS  Google Scholar 

  24. Gallagher JE, Blauth J, Fornadley JA. Perioperative ketorolac tromethamine and postoperative hemorrhage in cases of tonsillectomy and adenoidectomy. Laryngoscope 1995; 105: 606–9

    Article  PubMed  CAS  Google Scholar 

  25. Sutters KA, Levine JD, Dibble S, et al. Analgesic efficacy and safety of single-dose intramuscular ketorolac for postoperative pain management in children following tonsillectomy. Pain 1995; 16: 145–53

    Article  Google Scholar 

  26. Toradol package insert. Nutley, (NJ): Hoffman LaRoche, 1995

  27. Buck M. Clinical experience with ketorolac in children. Ann Pharmacother 1994; 28: 1009–13

    PubMed  CAS  Google Scholar 

  28. Rømsing J, Walther-Larsen S. Peri-operative use of nonsteroidal anti-inflammatory drugs in children: analgesic efficacy and bleeding. Anaesthesia 1997; 52: 673–83

    Article  PubMed  Google Scholar 

  29. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. JAMA 1996 Feb; 275; 5: 376–82

    Article  Google Scholar 

  30. Kehlet H, Dahl JB. Are perioperative nonsteroidal anti-inflammatory drugs ulceragenic in the short term? Drugs 1992; 44Suppl. 5: S38–S41

    Article  Google Scholar 

  31. Vane JR, Botting RM. The mode of action of anti-inflammatory drugs. Postgrad Med J 1990; 66Suppl. 4: S2–S17

    PubMed  CAS  Google Scholar 

  32. Bjaranason I, Thjodleifsson B. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology (Oxford) 1999; 38Suppl. 1: 24–32

    Article  Google Scholar 

  33. Fosslein E. Adverse effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28(2): 67–81

    Google Scholar 

  34. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 12: 33–9

    Article  Google Scholar 

  35. Traversa G, Walker AM, Ippolito FM, et al. Gastroduodenal toxicity of different anti-inflammatory drugs. Epidemiology 1995; 6(1): 49–54

    Article  PubMed  CAS  Google Scholar 

  36. Menniti-Ippolito F, Maggini M, Raschetti R, et al. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. Eur J Clin Pharmacol 1998; 54(5): 393–7

    Article  PubMed  CAS  Google Scholar 

  37. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6

    Article  PubMed  CAS  Google Scholar 

  38. Garcia Rodriguez LA, Jick H. The risk of upper gastrointestinal bleeding and/or perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72

    Article  PubMed  CAS  Google Scholar 

  39. Cummings DM, Amadio P. A review of selected newer nonsteroidal anti-inflammatory drugs. Am Family Physician 1994 Apr; 49; 5: 1197–202

    Google Scholar 

  40. Kenny GN. Potential renal, haematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992; 44Suppl. 5: S31–S6

    Article  Google Scholar 

  41. Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med 1990; 112(8): 559–60

    PubMed  CAS  Google Scholar 

  42. Henrich WL, Agodoa LE, Barrett B, et al. National Kidney Foundation Position Paper: analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162–5

    Article  PubMed  CAS  Google Scholar 

  43. DuBose Jr TD, Molony DA, Verani R, et al. Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 1994; 344: 515–8

    Article  Google Scholar 

  44. Aitken HA, Burns JW, McArdle CS, et al. Effects of ketorolac trometamol on renal function. Br J Anaesth 1992; 68: 481–5

    Article  PubMed  CAS  Google Scholar 

  45. Ready LB, Bown CR, Stahigren LH, et al. Evaluation of intravenous ketorolac administered by bolus or infusion for treatment of postoperative pain. Adouble-blind, placebo-controlled, multicenter study. Anesthesiology 1994; 80: 1277–86

    Article  PubMed  CAS  Google Scholar 

  46. Rao TRK, Naidu MUR, Shobha JC, et al. Renal effects of oral ketorolac in patients with mild to moderate pain. Clin Drug Invest 1995; 9: 111–5

    Article  Google Scholar 

  47. Myles PS, Power I. Does ketorolac cause postoperative renal failure: how do we assess the evidence? Br J Anaesth 1998; 80: 420–1

    Article  PubMed  CAS  Google Scholar 

  48. Feldman HL, Kinman JL, Berlin JA, et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 1997; 126: 193–9

    PubMed  CAS  Google Scholar 

  49. Sackett DL, Haynes RB, Guyatt GH, et al. Clinical epidemiology: a basic science for clinical medicine, 2nd ed. Boston: Little Brown, 1991: 283–302

    Google Scholar 

  50. Szezeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975; 1: 67–9

    Article  Google Scholar 

  51. Szezeklik A. aspirin-induced asthma: new insights into pathogenesis and clinical presentation of drug intolerance. Int Arch Allergy Immunol 1989; 90: 70–5

    Article  Google Scholar 

  52. Piado C, Castillo JA, Montserrat JM, et al. Aspirin intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989; 2: 127–9

    Google Scholar 

  53. Szezeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977; 60: 276–84

    Article  Google Scholar 

  54. Hebert WG, Scopelitis E. Ketorolac-precipitated asthma. South Med J 1994; 87; 2: 282–3

    Article  Google Scholar 

  55. Vicks SD, Dean RJ, Tenholder MF. Ketorolac induced respiratory failure in an aspirin sensitive asthmatic. Immunol Allergy Pract 1991; 13: 23–5

    Google Scholar 

  56. Dias MA, Biedlingmaier JF. Ketorolac-induced status asthmaticus after endoscopic sinus surgery in a patient with Samter’s triad. Arch Otolaryngol Head Neck Surg 1997; 117: S176–S8

    Article  CAS  Google Scholar 

  57. Zikowski D, Hord AH, Haddox JD. Ketorolac-induced bronchospasm. Anesth Analg 1993; 76: 417–9

    PubMed  CAS  Google Scholar 

  58. Haddow GR, Riley E, Isaacs R, et al. Ketorolac, nasal polyposis, and bronchial asthma: a cause for concern. Anesth Analg 1993; 76: 420–2

    PubMed  CAS  Google Scholar 

  59. Hammonds WD, Donnigan D. Problems in anesthesia: clinical use of ketorolac tromethamine 1993; 3: 268–80

    Google Scholar 

  60. Litvak KM, McEvoy GK. Ketorolac: an injectable non-narcotic analgesic. Clin Pharm 1990; 9(12): 912–35

    Google Scholar 

  61. Hennesey S, Kinman JL, Berlin JA, et al. Lack of hepatotoxic effects of parenteral ketorolac in the hospital setting. Arch Intern Med 1997; 157: 2510–4

    Article  Google Scholar 

  62. Walker JJ, Johnstone J, Lloyd J, et al. The transfer of ketorolac tromethamine from maternal to foetal blood. Eur J Pharmacol 1988; 3495: 509–11

    Google Scholar 

  63. Greer IA, Johnstone J, Tulloch I, et al. Effect of maternal ketorolac administration on platelet function in the newborn. Eur J Obstet Gynecol Reprod Biol 1988; 29(4): 257–60

    Article  PubMed  CAS  Google Scholar 

  64. Diemunsch P, Alt M, Diemunsch AM, et al. Post cesarean analgesia with ketorolac tromethamine and uterine atonia. Eur J Obstet Gynecol Reprod Biol 1997; 72(2): 205–6

    Article  PubMed  CAS  Google Scholar 

  65. Schorr SJ, Ascarelli MH, Rust OA, et al. A comparative study of ketorolac (Toradol) and magnesium sulfate for arrest of preterm labor. South Med J 1998; 91(11): 1028–32

    Article  PubMed  CAS  Google Scholar 

  66. Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 1998; 19(5): 389–410

    Article  PubMed  CAS  Google Scholar 

  67. Ostensen M. Nonsteroidal anti-inflammatory drugs during pregnancy. Scand J Rheumatol 1998; 107Suppl.: S128–S32

    Google Scholar 

  68. Schaab KC, Dickinson ET, Setzen G. Acute sensorineural hearing loss following intravenous ketorolac administration. J Emerg Med 1995; 13(4): 509–13

    Article  PubMed  CAS  Google Scholar 

  69. Otti T, Weindel M, Bastani B. Ketorolac induced acute reversible hearing loss in a patient maintained on CAPD. Clin Nephrol 1997; 47; 3: 208–9

    Google Scholar 

  70. Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol 1990; 10: 350–4

    PubMed  CAS  Google Scholar 

  71. Langlois R, Paquette D. Increased serum lithium levels due to ketorolac therapy. Can Med Assoc J 1994; 150(9): 1455–6

    CAS  Google Scholar 

  72. Iyer V. Ketorolac (Toradol) induced lithium toxicity. Headache 1994 Jul/Aug: 442–4

    Google Scholar 

  73. British National Formulary. 36th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1998

  74. Summers K, Wilson R. Ketorolac injection: a review of its safety and rational use in day case and major surgery. Pharmaceut Med 1994; 8; 115–34

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Utah School of Medicine, McKay-Dee Hospital, Department of Anaesthesiology, Salt Lake City, Utah, and Weber State University, 3939 Harrison Blvd, Ogden, Utah, 84401, USA

    Douglas J. Reinhart

Authors
  1. Douglas J. Reinhart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas J. Reinhart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reinhart, D.J. Minimising the Adverse Effects of Ketorolac. Drug-Safety 22, 487–497 (2000). https://doi.org/10.2165/00002018-200022060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200022060-00007

Keywords

Search

Navigation